HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
August 28, 2023 13:16 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who suffered substantial losses to submit your losses now. Visit:...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Sage Therapeutics (SAGE) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
August 21, 2023 13:37 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who suffered substantial losses to submit your losses now. Visit:...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud
February 27, 2020 19:39 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors with losses in excess of $100,000 to submit their losses now to learn if they...